Detalhe da pesquisa
1.
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.
Lung
; 201(3): 255-266, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37261531
2.
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Lung
; 199(2): 121-129, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33825965
3.
Gefapixant in two randomised dose-escalation studies in chronic cough.
Eur Respir J
; 55(3)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31949115
4.
Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis.
Ther Adv Respir Dis
; 18: 17534666241236025, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38501735
5.
Patterns of Cough Medication Prescribing among Patients with Chronic Cough in Florida: 2012-2021.
J Clin Med
; 12(19)2023 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37834931
6.
Effective use of 20% subcutaneous immunoglobulin therapy in a man with preexisting thrombi.
Ann Allergy Asthma Immunol
; 118(1): 115-116, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27876304
7.
Evaluation of Cough Medication Use Patterns in Ambulatory Care Settings in the United States: 2003-2018.
J Clin Med
; 11(13)2022 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35806956
8.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Lancet Respir Med
; 8(8): 775-785, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32109425